FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087879951> ?p ?o ?g. }

• W2087879951 endingPage "2317" @default.
• W2087879951 startingPage "2310" @default.
• W2087879951 abstract "Treatment of cancer associated thrombosis The treatment of cancer-associated venous thromboembolic disease is complex due to an increased risk of thrombotic recurrence and bleeding under treatment. During the first 6 months, low molecular weight heparins are more effective than vitamin k antagonists without increasing the risk of bleeding. Direct oral anticoagulants (doacs) have at least comparable efficacy to delateparin. The hemorrhagic risk of doacs is comparable or higher than that of dalteparin, but seems to depend on the doac studied and, at least for some of them, on the location of the tumor. Beyond the 6th month, the cura-tive anticoagulant treatment is continued as long as the cancer is active with low molecular weight heparin if it is well tolerated and effective or by using a doac at full dose while waiting for the results of a randomized trial comparing the efficacy and safety of half-dose versus full-dose of apixaban.Traitement de la maladie thromboembolique veineuse associée au cancer Le traitement de la maladie thromboembolique veineuse associée au cancer est plus complexe du ait de l’augmentation du risque de récidive thrombotique et d’hémorragie sous traitement. Au cours des six premiers mois, les héparines de bas poids moléculaire sont plus efficaces que les antivitamine-k sans augmentation du risque hémorragique. Versus la daltéparine, l’efficacité des anticoagulants oraux directs (aod) est au moins comparable. Le risque hémorragique lié aux aod est comparable ou supérieur à celui de la daltéparine, mais semble dépendre de l’aod étudié et, au moins pour certains d’entre eux, de la localisation de la maladie tumorale. Au-delà du sixième mois, le traitement anticoagulant curatif est poursuivi tant que le cancer est actif, avec l’héparine de bas poids moléculaire si elle est bien tolérée et efficace, ou un anticoagulant oral direct à pleine dose, en attendant les résultats d’un essai randomisé en cours comparant l’efficacité et la tolérance de l’apixaban à demi-dose et à pleine dose." @default.
• W2087879951 created "2016-06-24" @default.
• W2087879951 creator A5002706828 @default.
• W2087879951 creator A5084117447 @default.
• W2087879951 date "2013-10-03" @default.
• W2087879951 modified "2023-10-18" @default.
• W2087879951 title "Treatment of cancer-associated thrombosis" @default.
• W2087879951 cites W1482298218 @default.
• W2087879951 cites W1489164569 @default.
• W2087879951 cites W1503574249 @default.
• W2087879951 cites W1524501969 @default.
• W2087879951 cites W1562165033 @default.
• W2087879951 cites W1848837409 @default.
• W2087879951 cites W1955610473 @default.
• W2087879951 cites W1964312065 @default.
• W2087879951 cites W1964608845 @default.
• W2087879951 cites W1964650220 @default.
• W2087879951 cites W1969803003 @default.
• W2087879951 cites W1975897275 @default.
• W2087879951 cites W1975912868 @default.
• W2087879951 cites W1975927544 @default.
• W2087879951 cites W1976999482 @default.
• W2087879951 cites W1978080273 @default.
• W2087879951 cites W1984833612 @default.
• W2087879951 cites W1988033053 @default.
• W2087879951 cites W1994229246 @default.
• W2087879951 cites W1996797718 @default.
• W2087879951 cites W2000402978 @default.
• W2087879951 cites W2003601153 @default.
• W2087879951 cites W2010481138 @default.
• W2087879951 cites W2023234945 @default.
• W2087879951 cites W2024789639 @default.
• W2087879951 cites W2029596738 @default.
• W2087879951 cites W2031156548 @default.
• W2087879951 cites W2037052545 @default.
• W2087879951 cites W2041283702 @default.
• W2087879951 cites W2041459472 @default.
• W2087879951 cites W2050413041 @default.
• W2087879951 cites W2054962585 @default.
• W2087879951 cites W2055583528 @default.
• W2087879951 cites W2060501158 @default.
• W2087879951 cites W2060728327 @default.
• W2087879951 cites W2062522570 @default.
• W2087879951 cites W2064070223 @default.
• W2087879951 cites W2064230977 @default.
• W2087879951 cites W2064982023 @default.
• W2087879951 cites W2068118996 @default.
• W2087879951 cites W2069890646 @default.
• W2087879951 cites W2070112905 @default.
• W2087879951 cites W2077585688 @default.
• W2087879951 cites W2084667267 @default.
• W2087879951 cites W2090141832 @default.
• W2087879951 cites W2101131613 @default.
• W2087879951 cites W2102537088 @default.
• W2087879951 cites W2103029594 @default.
• W2087879951 cites W2112378432 @default.
• W2087879951 cites W2115019673 @default.
• W2087879951 cites W2115787552 @default.
• W2087879951 cites W2116844576 @default.
• W2087879951 cites W2118092611 @default.
• W2087879951 cites W2119426003 @default.
• W2087879951 cites W2124833016 @default.
• W2087879951 cites W2129838844 @default.
• W2087879951 cites W2130199362 @default.
• W2087879951 cites W2134683286 @default.
• W2087879951 cites W2135387854 @default.
• W2087879951 cites W2138438886 @default.
• W2087879951 cites W2139785591 @default.
• W2087879951 cites W2143130433 @default.
• W2087879951 cites W2147143600 @default.
• W2087879951 cites W2148342404 @default.
• W2087879951 cites W2156074347 @default.
• W2087879951 cites W2162193963 @default.
• W2087879951 cites W2162398328 @default.
• W2087879951 cites W2166046225 @default.
• W2087879951 cites W2171773051 @default.
• W2087879951 cites W2312814626 @default.
• W2087879951 cites W4236047329 @default.
• W2087879951 cites W4247355438 @default.
• W2087879951 cites W4255679514 @default.
• W2087879951 doi "https://doi.org/10.1182/blood-2013-04-460162" @default.
• W2087879951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35638950" @default.
• W2087879951 hasPublicationYear "2013" @default.
• W2087879951 type Work @default.
• W2087879951 sameAs 2087879951 @default.
• W2087879951 citedByCount "138" @default.
• W2087879951 countsByYear W20878799512013 @default.
• W2087879951 countsByYear W20878799512014 @default.
• W2087879951 countsByYear W20878799512015 @default.
• W2087879951 countsByYear W20878799512016 @default.
• W2087879951 countsByYear W20878799512017 @default.
• W2087879951 countsByYear W20878799512018 @default.
• W2087879951 countsByYear W20878799512019 @default.
• W2087879951 countsByYear W20878799512020 @default.
• W2087879951 countsByYear W20878799512021 @default.
• W2087879951 countsByYear W20878799512022 @default.
• W2087879951 countsByYear W20878799512023 @default.
• W2087879951 crossrefType "journal-article" @default.

• next